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An overview of structurally diversified anticonvulsant agents
There are several limited approaches to treat epilepsy in 
hospitals, for example, using medicines, surgery, electrical 
stimulation and dietary interventions. Despite the avail-
ability of all these new and old approaches, seizure is par-
ticularly difficult to manage. The quest for new antiepileptic 
molecules with more specificity and less CNS toxicity 
 continues for medicinal chemists until a new and ideal 
drug arrives. This review covers new antiseizure molecules 
of different chemical classes, the exact mode of action of 
which is still unidentified. Newer agents include sulfon-
amides, thiadiazoles, semi- and thiosemicarbazones, pyr-
rolidine-2,5-diones, imidazoles, benzothiazoles and amino 
acid deriva tives. These new chemical entities can be useful 
for the design and development of forthcoming antiseizure 
agents.
Keywords: antiepileptic agents, sulfonamides, imidazoles, 
thiadiazoles, benzothiazoles and amino acid derivatives
INTRODUCTION
Epilepsy is a collective term for a group of chronic CNS disorders. All kinds of epilep-
sies display the occurrence of unprovoked, excessive, sudden, self-regulated neuronal dis-
charge that results in a seizure. Because of excessive neuronal discharge, the finely orga-
nized pattern of the integrative activity of the brain is abolished (1).
Prevalence of the disease is observed in every corner of the world, with underdeve loped 
countries being more vulnerable. It is estimated that almost 50 million people around the 
world are affected by epilepsy (2). Older people are more prone to epileptic spell (3). The 
exact etiology of the disease is still unknown. However, factors associated with epilepsy 
include brain trauma, strokes, brain cancer and drug and alcohol misuse, among others. 
The multifactorial origin of the disease produces a high degree of disablement to successful 
discovery of antiepileptic drugs (4). In many cases, there is no direct family relation to the 
epileptic condition at all. However, some researchers have confirmed that some special 
types of epilepsy take place more often in some families. It was recently revealed that such 
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types of epilepsy were connected with the transfer of specific genes from one generation 
to another (5–10). There are many mutated genes responsible for various types of inheritable 
epilepsies, for example, familial nocturnal frontal lobe epilepsy is caused by inheritance 
of mutated CHRNA2, CHRNA4 and CHRNB2 genes. In the same way, febrile seizures, 
generalized epilepsy with febrile seizures plus and Dravet syndrome are caused by inheri-
tance of mutated SCN1A, SCN2A, SCN2B and GABRG2 genes. Many studies have confirmed 
that epigenetically facilitated regulation of Na+ channel genes (SCN1A, SCN1B, SCN2A 
and SCN3A) associated with generalized epilepsy with febrile seizures plus (GEFS+) are 
mediated via DNA methylation and methyl-CpG-binding domain 2 (MBD2) binding (11). 
Some antiepileptic drugs produce epigenetic changes. For example, valproate induces 
 defects of epigenetic transcriptional regulatory mechanisms in glial cells, resulting in 
 reduced cell proliferation, which may in turn lead to cognitive dysfunction or mental 
 illness (12, 13). 
Over the past ten years, a large number of new antiepileptic drugs (AEDs) and non-
pharmacologic remedies have been added to treat epilepsy. The new drugs are designed 
to address specific pathophysiologic defects such as seizure generation or spread where 
the old medicines are not useful any more. Other novel approaches to control epilepsy 
include electrical stimulation devices, such as vagus nerve stimulator (14–16), deep brain 
stimulation (DBS) (17, 18) and dietary interventions (ketogenic diet) (19–22). Despite the 
availability of all new and old AEDs, along with the arrival of new techniques, seizures 
are particularly challenging to treat. The old generation antiepileptic drugs (AEDs) such 
as phenobarbital, primidone, phenytoin, carbamazepine, ethosuximide and benzodiazepine 
are potent and extensively used but exhibit considerable adverse effects and also fail to ade-
quately control seizures (23). On the other hand, new AEDs, for example gabapentin, topi-
ramate, lamotrigine, levetiracetam, vigabatrin, and rufinamide are not as potent as the old 
AEDs and are used as an add-on therapy. They all exhibit significant CNS-related and other 
side effects (24). This study suggests that only a small number of new AEDs  adequately manage 
major types of epilepsy, the remaining drugs control only one or two types. The undesired 
side effects and failure to control the major types of epilepsy compel the researchers to find 
candidates that would meet all the requirements for an ideal drug.
The antiseizure drugs, which are currently prescribed in the clinics, are categorized 
based on their mode of action as follows (Fig. 1): 
(i)  drugs that block the sodium channel, for example, phenytoin, carbamazepine, 
oxcarbazepine, etc.,
(ii)  drugs that activate GABA-mediated inhibitory action, such as benzodiazepines, 
barbiturates, vigabatrin, tiagabine,
(iii)  drugs that block the Ca2+ channel, for example, pregabalin, gabapentine, etc.,
(iv)  drugs that inhibit glutamate receptors (both NMDA and AMPA), for example, 
felbamate, topiramate, etc.
Some drugs possess a combination of actions, often coupled with additional and un-
known mechanisms (25, 26); these include valproic acid, lamotrigine, zonisamide, etc.
The newly designed and synthesized antiepileptic agents have been surveyed over 
the last few years. The diversity of chemical structures and various modes of action of 
anticonvulsant agents make it hard to attain a universal way of discovering new drugs. 
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Novel antiepileptic molecules are discovered via screening or modification in the structure 
of already existing drugs but not by a mechanism-based design.
This review highlights new antiseizure agents containing various chemical structures 
whose exact mode of action is unknown. These newly synthesized analogues comprise 
sulfonamides, heterocyclic compounds, functionalized amino acids, and others. These 
chemical classes of compounds can be useful for the design and development of new anti-
epileptic drugs in the future.
NEW ANTICONVULSANT AGENTS: A STRUCTURE BASED REVIEW
Sulfonamide derivatives
This class of drugs has displayed a large number of clinical uses. Some of these drugs 
are used as antimicrobials, also called sulpha drugs. Some are carbonic anhydrase (CA) 
inhibitors, which are used as diuretics and antiepileptic drugs. In search of newer anticon-
vulsant agents, researchers discovered acetazolamide and methazolamide (Fig. 2). In gen-
eral, these drugs are 5-membered heterocycles containing a sulfonamide and an amide as 
well as a 1,3,4-thiadizole nucleus. They exhibit potent carbonic anhydrase inhibitory activ-
ity. Topiramate and zonisamide are recently developed antiepileptic drugs bearing differ-
ent sulfonamide groups in their structure (Fig. 2). Scozzafava and Supuran (27–32) devel-
oped several new carbonic anhydrase inhibitors, which are mainly derivatives of 
sulfonamide. Recent progress in the development of anticonvulsant agents containing 
sulfonamide moiety is summarized in Table I. 
Fig. 1. Mechanism of action of antiepileptic drugs (α2δ – auxiliary subunit of voltage dependent Ca2+ 
channels, AMPA – α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid, GABA – γ-aminobutyric 
acid, Gly – glycine, Glu – glutamate, NMDA – N-methyl-D-aspartate, SSA – succinate semialdehyde, 
SV2 – synaptic protein 2).
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Fig. 2. Antiepileptic drugs containing a sulfonamide group.


















Thiadiazoles are five-membered heterocyclic rings bearing two nitrogen atoms and 
one sulfur with two nitrogen-carbon double bonds (C=N). These conjugated double bonds 
between atoms provide the thiadiazole ring aromatic property. Four likely structures can 
be perceived on the basis of the locations of one sulfur and two nitrogen atoms (Fig. 3). 
These structures do not interchange and are hence structural isomers (not tautomers). 
Various isomers of thiadiazole are used as the basic moiety in the process of drug discovery 
and development (36–38). 
Table II gives an overview of thiadizole-containing new derivatives that display sig-
nificant antiseizure activity in various animal models.
Semi- and thiosemi-carbazones as anticonvulsant agents
During the last two decades, semicarbazones have been extensively investigated for 
their anticonvulsant properties (51–54). In the conventional screening process, 4-(4-fluoro-
phenoxy) benzaldehyde semicarbazone was discovered as a lead molecule against the elec-
troshock (MES) seizure test. The protective index of this compound is higher than that of 
carbamazepine, phenytoin and valproate (55). Later on, a large number of scholars have 
attempted to find new molecules with significant anticonvulsant activity (Table III). 
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Two carbon side chains are 
important for showing 
anticonvulsant activity. 
Substitutions in the terminal 
sulphonamide moiety 
improve the lipophilic 
character, giving better CNS 
activity. 











2a; R=3-NO , 2-Cl best anti-MES activity at 0.5 h3
2b; R=2-CH , 2-CH(CH ) , 4-NO , 2-Cl best anti-3 3 2 3
MES activity at 4 h
2c; R=3-CH and 2-CH highly neurotoxic3 3
Certain substituents, such as 
Cl, CH3, and NO3, in phenyl 
bound to nitrogen produce 
highly active analogues in 
the electroshock seizure test.

















strated protection in MES 
and scPTZ seizure models.
Siddiqui et al. 
(35)
CNS – central nervous system, MES – maximal electroshock seizure, scPTZ – subcutaneous pentylenetetrazole
Pyrrolidine-2,5-diones as anticonvulsants
Derivatives of pyrrolidine-2,5-dione, as heterocyclic compounds, have been widely 
applied in medicinal chemistry. They exhibit abundant biological activities, especially in 
seizure and tyrosinase inhibitory action. Therefore, progress of new and efficient appro-
aches for the preparation of multi-substituted pyrrolidine-2,5-dione derivatives is a burning 
issue in organic and medicinal chemistry (61).
Literature survey has revealed that Obniska and Kaminski (62–66), along with other 
researchers, worked extensively on pyrrolidin-2,5-diones as potential anticonvulsant 
agents. Some recently developed anticonvulsant agents having pyrrolidin-2,5-dione in 
their structure are presented in Table IV. 
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5; R =4; p-C2 -O-C6H5 H4
Compounds 4 and 5 showed 
high activity against the 
scPTZ model.









Derivative 6 was observed to 
be highly active in MES and 
scPTZ test models.







7a; 2-Cl, R1 = H
7b; 4-Cl, R1 = H
8a; 2-Cl, R1 = CH2-C6H5
8b; 4-Cl, R1 = CH2-C6H5
9a; 2-Cl, R1 = CH2(4-Cl)C6H4
9b; 4-Cl, R1 = CH2(4-Cl)C6H4
These compounds displayed 
moderate to good activity in 
the MES test.







10a; R = C6H5, Ar = 4-Cl-C6H4
10b; R = 3-Cl-C6H4, Ar = 4-Cl-C6H4
10c; R = 4-Cl-C6H4, Ar = pyridine
These compounds exhibited 
excellent anti-MES and 
anti-scPTZ activity.



























Compounds 11, 12 and 13 
were the most active against 
both electroshock (MES) and 
chemoshock (PTZ) with an 
ED50 20.11 to 35.33 mg kg–1.
Foroumadi et al. (43)
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This compound showed 
anti-seizure activity against 
MES, scPTZ with a high 
protective index.














R = C6 ; R1 = 4-NO2H5
Compound 15 was observed 
to be the most protective 
against both electroshock 
(MES) and chemoshock 
(scPTZ).













R = C6H5, R1 = 4-OCH3
16
R1
Analogue 16 showed 
significant protection in 
MES and scPTZ seizure 
models without any 
neuromotor impairment.












17a; R = 4-Br, R = Cl1
17b; R = 3-Cl, R = Cl1
These two derivatives (17a,b) 
exhibited total protection in 
the electroshock (MES) 
seizure test.














Analogues 18 and 19 were 
found to be promising 
antiepileptic agents.































Compounds 20 and 21 
confirmed the moderately 
protective effect against 
electroshock seizure similar 
to that of the standard drug 
phenytoin.











22a; R = cyclohexyl
22b; R = 4-Cl-C H -6 4
22c; R = 4-OCH -C H -3 6 4
Three analogues 22a-c were 
found to be protective at a 




ED50 – median effective dose, MES – maximal electroshock seizure, PTZ – pentylenetetrazole,  scPTZ – subcutane-
ous pentylenetetrazole
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This compound was found 
highly active in the MES test 
without any neuromotor 
impairment.



















Analogues 24 and 25 showed 
promising outcomes against 
the MES seizure model with 
lesser or no neuromotor 
impairment.









Analogue 26 showed signifi-
cant activity against MES, 
scPTZ and scSTY seizure tests 
without any neuromotor 
impairment
Yogeeswari et al. 
(58)
27a; Ar = naphthyl, X = S, R= 3-Cl
27b; Ar = biphenyl, X = S, R= 4-F










R All three derivatives were 
found to be highly active in 
the MES test.
Çalış et al. (59)
28a; R = 3-Br
28b; R = 4-F







Analogues 28a-c showed the 
highest degree of protection in 
MES and scPTZ seizure 
models.
Azam et al. (60)
MES – maximal electroshock seizure, scPTZ – subcutaneous pentylenetetrazole, scSTY – subcutaneous strychnine
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Highly active derivative 29 with 
ED50 20.78 mg kg–1, when 
administered orally to rats and 30 
with ED50 132.13 mg kg–1 after 
i.p. injection to mice in the MES 
test.
Obniska et al. 
(67)
31a; R = 2-Cl, R1 = 2-Cl
31b; R = 3-Cl, R1 = 2-Cl
31c; R = 3-Cl, R1 = 4-Cl





R In anti-MES and anti-scPTZ 
tests, compounds 31c and 31d 
were highly active. 
In psychomotor seizure 6-Hz 
test, compounds 31a and 31b 
were highly active.










32a; R1 = H, R2 = H, R3 = 3-CF3
32b; R1 = CH3, R2 = H, R3 = 4-Cl
32c; R1 = CH3, R2 = CH3, R3 = 4-Cl
32d; R1 = CH3, R2 =CH3, R3 = 3-CF3
Most anti-MES and anti-scPTZ 
compounds were 32a-d.
32a and 32c displayed high 
activity in the 6-Hz psychomo-
tor seizure screening.
Kamiński et al. 
(69)
33a; R1 = C6H5, R2 = C6H5, R3 = CH2CH2CH2OH
33b; R1 = C6H5, R2 = CH3, R3 = CH2CH2CH2OH







Compounds 33a-c showed 
moderate to good activity in 
anti-MES and anti-scPTZ tests 
as well as 6-Hz psychomotor 
seizure screening.
Obniska et al. 
(70)
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34a; R = H, X=N, R = 2-pyrimidinyl1
34b; R = H, X=O
34c; R = 2-Cl, X = CH, R = benzyl1
34d; R = 2-Cl, X = O
Compound 34a was Anti-MES 
and anti-scPTZ active. 
34a, 34b and 34d were active 
in the 6-Hz psychomotor 
seizure screening.
34b was found highly effective 
against status epilepticus.










Compound 35 was found to be 
the most active in the MES 
test, with an ED50 equivalent 
to 30.3 mg kg–1 (per os in rats). 







Compound 36 was the most 
favorable analogue against the 
6-Hz psychomotor seizure 
model.








37a; R = C , R = 3,4-diCl1 3 2H
37b; R = H, R = 3,4-diCl1 2
37c; R = C , R = 3-CF1 3 2 3H
All three derivatives 37a-c 
were reported highly active in 
MES and scPTZ tests. 








38a 38b 38c; R = H, ; R = 2-F, ; R=4-F,













In the MES seizure test, 38b, 
38c and 38e were the most 
active compounds. 
In the scPTZ test, 38a and 39 
were the most active com-
pounds.
Some compounds were also 
found active against the 
psychomotor seizure 6-Hz test, 
for example, 38d and 40.
Obniska et al. 
(75)
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41a; R1 = CH3, R2 = H, R3 = 2-Cl
41b; R1 = CH3, R2 = H, R3 = 3-Cl








Broad spectra of activities 
across the preclinical seizure 
models were displayed by 
compounds 41b, 41c and 42.
Besides anticonvulsant 
properties, compound 41a 
diminished the pain responses 
in the formalin model of tonic 
pain in mice.
Kamiński et al. 
(76)
43a; R = CH3, R1 = 2,3-diCl








Analogues 43a and 43b 
exhibited antiseizure activity 
in pilocarpine-induced seizure 
models.










44a; R = C H , R = 3-Cl6 5 1
44b; R = C H , R = 3-CF6 5 1 3
The most active analogues 
were 44a having ED50 42.71 mg 
kg–1 in case of MES and ED50 
>150 mg kg–1 in case scPTZ, and 
44b with ED50 101.46 mg kg–1 in 
case of MES and ED50 72.59 mg 
kg–1 in case scPTZ.









Compound 45 was the most 
promising compound in all 
the antiseizure tests.
Rybka et al. 
(79)
ED50 – median effective dose, i.p. – intraperitoneally, MES – maximal electroshock seizure, scPTZ – subcutaneous 
pentylenetetrazole
Imidazoles as anticonvulsant agents
Imidazole and its analogues are five-membered heterocyclic structures having two 
 nitrogen atoms separated by one carbon atom. Recent studies have revealed that imidazole 
analogues have attracted a great deal of attention owing to their broad range of biological 
activities such as analgesic (80), anti-inflammatory (81), etc. Literature survey has also shown 
that imidazole-heterocyclic analogues could be an important class of antiseizure agents; an 
existing antiseizure drug, phenytoin, contains an imidazole ring (82). Some potent and re-
cently developed imidazole bearing anticonvulsant agents are summarized in Table V.
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Compound 46 was highly active 
with ED50 and TD50 values of 38.46 
mg kg–1 and 123.83 mg kg–1 in mice, 
and 20.44 mg kg–1 and 56.36 mg kg–1 
in rats.









Only compound 47 was found 
equally active as the standard drugs 
carbamazepine and phenytoin in the 
MES test.









Compound 48 showed the highest 
activity among the synthesized 
analogues in MES and scPTZ 
without any neuromotor impair-
ment or depressant effects on CNS.






Compound 49 was highly active 
against electroshock (MES) and 
chemoshock (scPTZ) models.





Compound 50 was found highly 
active in MES at both time intervals, 
i.e., 0.5 and 4 h, suggesting a rapid 
onset and long duration of action.
Ulloora et al. (87)
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Compound 51 emerged as a highly 
active candidate showing 100 % 
protection at a very low dose in the 
chemoshock (scPTZ) screen without 
any neuromotor impairment.
Attia et al. (88)
CNS – central nervous system, ED50 – median effective dose, MES – maximal electroshock seizure, scPTZ – subcu-
taneous pentylenetetrazole, TD50 – median toxic dose
Benzothiazoles as anticonvulsants
Benzothiazole belongs to the family of bicyclic heterocyclic compounds having the 
benzene nucleus fused with a five-membered ring comprising nitrogen and sulfur atoms. 
Benzothiazole is an important scaffold with a wide spectrum of biological activities (89).
Work on benzothiazoles as anticonvulsant agents started recently and now we have a 
modest number of articles that validate benzothiazoles as potential candidates for control-
ling seizures (Table VI) (90–100).
Functionalized amino acids (derivatives of amino acids) as anticonvulsants
Kohn and his team (101) revealed a novel class of anticonvulsants which were ana-
logues of amino acids, called functionalized amino acids. Functionalization of the amino 
and carboxyl terminal of amino acids with different substituents exhibits anticonvulsant 
activity (102–105).
Heterocyclic amino acid derivatives are based on a proline-like structure having a 
nitrogen-containing ring in which the nitrogen atom of heterocyclic moiety will serve as 
amino function and carboxylic group will be attached to the ring. Fig. 4 shows some hetero-
cyclic amino acid derivatives that are used as an add-on therapy for the treatment of 
 epilepsy.














Proline Nipecotic acid Tiagabine
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52a; R = CH3, R1 = CH3, R3 = NO3
52b; R = OCH3, R1 = CH3, R3 = NO3
52c; R = CH3, R1 = C6H5, R3 = H
Compounds 52a-c 
displayed 100 % activity in 
the MES test at both time 
intervals, 0.5 and 4 h, 
without any significant 
neurotoxicity.












53a; R = H, R1 = 6-F
53b; R = 2-Cl, R1 = 6-CH3
53c; R = 4-OCH3, R1 = 6-Br
Compounds 53a-c showed 
significant activity in MES 
and scPTZ tests with no 
sign of neurotoxicity.









Compound 54 was highly 
active, with ED50 40.96 mg 
kg–1 in case of the MES test, 
85.16 mg kg–1 in case of the 
sc-PTZ test and TD50 of 
347.6 mg kg–1.














55a; R = 4-Br
55b; R = 3-Cl
Derivatives 55a,b  
displayed complete 
protection in the MES 
seizure test.














56a; R = CH3
56b; R = C H6 5
Both analogues 56a,b 
showed significant activity 
in MES and scPTZ tests 
after 0.5 h of administra-
tion, with less or equiva-
lent toxicity compared to 
carbamazepine.












Highly active molecule 57 
showing 100 % protection 
in the MES test.
Farag et al. 
(95)
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58a; R = 3,4-diCl
58b; R = 2-OCH3










R Compounds 58a-c 
exhibited significant 
anticonvulsant activity in 
the MES test at the dose of 
30 mg kg–1 comparable to 
the standard drug 
phenytoin.








Compound 59 was found 
to be the most active in the 
MES seizure test with ED50 
value of 13.6 mg kg–1.









Compound 60 was highly 
active with ED50 of 8.0 mg 
kg–1 and PI = 15.0 in the 
MES test.









61a; R = Cl, R = H1 2
61b; R = N , R = H1 2 2O
61c; R = N , R = 4-Cl1 2 2O
61d; R = Cl, R = 4-Cl1 2
R
Compounds 61a-d displayed 
significant protection in the 
MES test after 0.5 and 4 h. 










62a; R = CH C H ( -F)2 6 4 m
62b; R = CH C ( -F)2 6 4H p
The two analogues 62a,b 
were the most potent, 
having ED50 value of 50.8 
and 54.8 mg kg–1 in the 
MES test and 76.0 and 52.8 
mg kg–1 in the scPTZ 
seizure test, resp.
 Liu et al. 
(100)
ED50 – median effective dose, MES – maximal electroshock seizure, PI – protective index, scPTZ – subcutaneous 
pentylenetetrazole, TD50 – median toxic dose
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Table VII. Recently developed functionalized amino acids as anticonvulsants
Compound Summary/conclusion Reference







Compound 63 showed highly 
inhibitory effect of GAT1 
comparable to tiagabine.










64a; R1 2= H, R = H
64b; R1 2= Br, R = H
64c; R1 2 5 2= C H , R = H
64d; R1 2 3= Cl, R = CH
Compound 64a demonstrated 
weak seizure protection in the 
MES seizure screening (300 
mg kg–1). Analogues 64b–d 
displayed significant 
protection in scPTZ seizures 
tests.










65a; X = Cl
65b; X = OCF3
2"
3"
The two analogues (65a,b) 
displayed a high protective 
index in comparison with 
many antiseizure drugs when 
tested against MES in mice 
(intraperitoneally) and rats 
(intraperitoneally and orally).








The ED50 of compound 66 in 
the MES test, upon i.p. 
administration to mice, was 
19.1 mg kg–1.
Usifoh et al. 
(110)
ED50 – median effective dose, GAT1 – GABA transpoter-1, i.p. – intraperitoneally, MES – maximal electroshock 
seizure, MES – maximal electroshock seizure, scPTZ – subcutaneous pentylenetetrazole
Tiagabine, a heterocyclic amino acid analogue with nipecotic acid function, is used as 
a prescription medicine for the treatment of partial seizures (106). A fair number of newly 
synthesized amino acid derivatives as potential anticonvulsant agents are summarized in 
Table VII.
CONCLUSIONS
The present review provides an insight into new chemical entities that have shown 
promising antiepileptic activity and updates the knowledge of currently available AEDs.
Many of the agents shown in this review have been screened by the antiepileptic drug 
development program. Their antiseizure activity has been assessed through in vivo screen-
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ings, although the exact mode of action of many agents is still unidentified. Some of the 
newer anticonvulsant analogues are prepared via structural changes of pre-existing drugs, 
whereas others have been developed with the specific objective of altering targets. Such 
new synthetic agents generally come from different chemical groups. Some of them repre-
sent compounds containing five- or six-membered or other heterocyclic rings in their 
structure. However, a significant number of literature reports suggest that analogues of 
amino acids can act as valuable antiseizure agents. Discovery of a large number of active 
leads may also help in finding alternative drug candidates in the event of drug tolerance. 
Compounds mentioned in this review can be used in the future as potential drug candi-
dates with more efficacy and lesser toxicity.
Abbreviations, acronyms, symbols. – AEDs – antiepileptic drugs; AMPA – α-amino-3-hydroxy-5- 
-methyl-4-isoxazolepropionic acid; CA – carbonic anhydrase; CHRNA2 – cholinergic receptor nicotinic 
alpha 2 subunit; CHRNA4 – cholinergic receptor nicotinic alpha 4 subunit; CHRNB2 – cholinergic 
receptor nicotinic beta 2 subunit; CNS – central nervous system; DBS – deep brain stimulation; 
ED50 – median effective dose; GABA – γ-aminobutyric acid; i.p. – intraperitoneal; NMDA – N-methyl- 
-D-aspartate; GABRG2 – gamma-aminobutyric acid type A receptor gamma 2 subunit; GAT1 – GABA 
transpoter-1; GEFS+ – generalized epilepsy with febrile seizures plus; MBD2 – methyl cytosine- 
-phosphate-guanine binding domain 2; MES – maximal electroshock seizure; PI – protective index; 
SCN1A – sodium voltage-gated channel alpha 1 subunit; SCN2A – sodium voltage-gated channel 
alpha 2 subunit; SCN3A – sodium voltage-gated channel alpha 3 subunit; SCN1B – sodium voltage-gated 
channel beta 1 subunit; SCN2B – sodium voltage-gated channel beta 2 subunit;  scPTZ – subcutaneous 
pentylenetetrazole; SSA – succinate semi-aldehyde; SV2 – synaptic vesicle protein 2; TD50 – median 
toxic dose
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